Immunovant, Inc.IMVTNASDAQ
Loading
R&D Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+36.5%
5Y CAGR+42.8%
Year-over-Year Change
Research and development spending
3Y CAGR
+36.5%/yr
vs +58.0%/yr prior
5Y CAGR
+42.8%/yr
Recent deceleration
Acceleration
-21.4pp
Decelerating
Percentile
P100
Near historical high
vs 5Y Ago
5.9x
Strong expansion
Streak
7 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| TTM | $408.02M | +13.1% |
| 2025 | $360.92M | +69.5% |
| 2024 | $212.93M | +32.9% |
| 2023 | $160.26M | +57.4% |
| 2022 | $101.81M | +48.4% |
| 2021 | $68.60M | +43.1% |
| 2020 | $47.93M | +86.2% |
| 2019 | $25.73M | -81.0% |
| 2018 | $135.26M | - |